Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Vaccine development and innovation stories

Oct 6, 2026

Bangladesh considers dengue vaccine trials as outbreak kills hundreds

Bangladesh is considering clinical trials for a dengue vaccine after hundreds of deaths and thousands of hospitalizations from the mosquito-borne disease. The outbreak has worsened through September, with at least 233 deaths reported and experts warning that weather conditions could fuel further spread.

Oct 6, 2026·3 sources
00
Oct 5, 2026

Vaxcyte pneumococcal vaccine succeeds in Phase 3 trial

Vaxcyte's experimental pneumococcal vaccine generated immune responses comparable to Pfizer and Merck vaccines in a Phase 3 trial, positioning it to compete in the lucrative vaccine market.

Oct 5, 2026·3 sources
00
Oct 1, 2026

Lyme disease vaccine shows safety in children aged 5-17 in phase 3 trial

A four-dose series of an investigational Lyme disease vaccine demonstrated safety and tolerability in children and teens aged 5-17 years in phase 3 randomized controlled trial results presented at the American Academy of Pediatrics 2026 National Conference. The development comes as drugmakers race to create effective defenses against Lyme disease amid intensifying tick seasons.

Oct 1, 2026·3 sources
00
Sep 19, 2026

mRNA cancer vaccines expand beyond melanoma to lung and pancreatic cancer trials

Following the breakthrough success of an mRNA melanoma vaccine, clinical trials are now underway testing similar vaccine technology for lung cancer, pancreatic cancer, and other diseases.

Sep 19, 2026·1 source
00
Sep 11, 2026

India administers 8 million HPV vaccine doses in six months since national campaign launch

India has crossed 8 million (80 lakh) HPV vaccinations since launching its nationwide campaign in February 2026, targeting 14-year-old girls. The initiative represents a major milestone in the country's cervical cancer prevention efforts.

Sep 11, 2026·3 sources
00
Sep 8, 2026

FDA Approves First mRNA Flu Vaccine for Adults 50 and Older

Moderna's mFLUSIVA becomes the first mRNA-based seasonal influenza vaccine to receive FDA approval.

Sep 8, 2026·4 sources
00
Sep 1, 2026

GSK advances mRNA flu vaccine to late-stage trial after strong mid-stage results

GSK will advance its mRNA-based seasonal influenza vaccine to late-stage trials after mid-stage data showed it generated stronger immune responses than currently approved flu vaccines.

Sep 1, 2026·2 sources
00
Aug 28, 2026

Moderna raises $2.6B following major cancer vaccine trial success

Moderna completed an upsized note offering to support its cancer work shortly after achieving a significant win in a crucial clinical study of its mRNA cancer vaccine developed with Merck.

Aug 28, 2026·2 sources
00
Aug 20, 2026

Moderna gains $45 billion in market value after cancer vaccine breakthrough

Moderna's stock surged following positive data on its mRNA cancer vaccine developed with Merck, restoring investor confidence and bringing shares to levels not seen since 2024.

Aug 20, 2026·2 sources
00
Aug 19, 2026

Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence in late-stage trial

Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.

Aug 19, 2026·6 sources
00
Aug 6, 2026

FDA approves Moderna's mFlusiva, first mRNA-based flu vaccine in the United States

The Food and Drug Administration approved Moderna's mFlusiva on Wednesday, marking the first mRNA-based influenza vaccine authorized in the U.S. The vaccine is approved for adults aged 50 and older, representing a significant expansion of mRNA technology beyond COVID-19 vaccines.

Aug 6, 2026·6 sources
00
Aug 5, 2026

UK Approves First Trial of Moderna-Oxford mRNA Vaccine to Prevent Lynch Syndrome Cancers

UK regulators have authorized the INTERCEPT-Lynch Phase 1/2 trial of mRNA-4194, a preventive cancer vaccine developed by Moderna and the University of Oxford targeting people with Lynch syndrome, an inherited condition affecting 1 in 300 people with up to 80% lifetime cancer risk. The trial will begin dosing in summer 2026.

Aug 5, 2026·9 sources
00
Jul 30, 2026

Merck-Wellcome Joint Venture to Manufacture Experimental Ebola Vaccine for Congo Outbreak

Hilleman Laboratories, a Singapore-based partnership between Merck and Wellcome, is preparing to produce doses of an experimental vaccine targeting the rare Bundibugyo strain of Ebola amid a fast-spreading outbreak in the Democratic Republic of Congo.

Jul 30, 2026·1 source
00

Merseyside Woman Becomes First Patient Worldwide to Receive New Lung Cancer Vaccine in Clinical Trial

A lung cancer patient from Merseyside has become the first person in the world to receive a new experimental vaccine as part of an early-stage clinical trial involving 10 patients.

Jul 30, 2026
00
Jul 24, 2026

First Volunteer Vaccinated in World’s First Bundibugyo Ebola Vaccine Trial

Oxford University researchers administered the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola to a UK volunteer, as the deadly outbreak in the Democratic Republic of Congo has now killed over 1,000 people. Separate studies suggest existing Ebola vaccines may offer some cross-protection against this rare strain.

Jul 24, 2026·4 sources
00
Jul 16, 2026

Serum Institute of India to Manufacture Experimental TB Vaccine M72/AS01E in Partnership with Gates Medical Research Institute

The Serum Institute of India has signed an agreement with the Gates Medical Research Institute to manufacture M72/AS01E, a novel tuberculosis vaccine candidate currently in late-stage clinical trials. If approved, it would be the first new TB vaccine in over 100 years, with Serum Institute planning to invest over $100 million in production.

Jul 16, 2026·3 sources
00
Jul 13, 2026

Oxford Launches First Human Trial of Bundibugyo Ebola Vaccine Amid Congo Outbreak

The University of Oxford has begun the first human trial of a vaccine targeting Bundibugyo ebolavirus, accelerating efforts to combat an ongoing outbreak in the Democratic Republic of Congo. A US patient infected in Congo is being treated at a German hospital.

Jul 13, 2026·2 sources
00
Jul 9, 2026

Moderna Wins EU Contract for RSV Vaccine Supply

Moderna has secured a contract with the European Union to supply its respiratory syncytial virus (RSV) vaccine, expanding the company's vaccine portfolio beyond COVID-19.

Jul 9, 2026·1 source
00
Jun 26, 2026

European Commission Opens Antitrust Investigation Into Sanofi's Flu Vaccine Marketing Practices

The European Commission launched an antitrust probe into Sanofi for allegedly disparaging a rival's flu vaccine in its marketing campaigns, potentially violating competition rules.

Jun 26, 2026·3 sources
00
Apr 29, 2026

Seasonal Flu Vaccines May Reduce Severity of H5N1 Bird Flu Infections in Humans

Research suggests that seasonal influenza vaccination could provide cross-protection against H5N1 avian influenza, potentially reducing severity if the virus causes human infections during a pandemic scenario.

Apr 29, 2026·1 source
00
Apr 20, 2026

India Approves New Tuberculosis Vaccines for Adolescents Following Large Phase III Trial

India has approved new tuberculosis vaccines for adolescents, backed by a large, independent Phase III clinical trial led and funded by public science institutions. The vaccines represent a significant breakthrough in TB prevention, though officials note they are not a complete solution.

Apr 20, 2026·1 source
00
Apr 19, 2026

mRNA Cancer Vaccines Show Effectiveness Even Without Key Immune Cells in New Research

Scientists discovered that mRNA cancer vaccines can still destroy tumors even when a key immune cell type is missing, revealing unexpected mechanisms of action. The research advances understanding of how Nobel Prize-winning mRNA technology can be adapted from COVID-19 vaccines to fight cancer.

Apr 19, 2026·1 source
00
Apr 10, 2026

Two New Tuberculosis Vaccines Prove Safe But Fail to Provide Broad Protection in India Trial

A large clinical trial in India published in The BMJ found two new TB vaccines are safe for adults and children but do not offer protection against all forms of tuberculosis.

Apr 10, 2026·1 source
00

Top claims

  • ▪State Minister for Health M.A. Muhit announced that Bangladesh is considering vaccine trials because all four dengue virus serotypes are now circulating in the country.
  • ▪Medical entomologist Kabirul Bashar stated that September's rains could drive dengue infections through October 2026 due to a 45 to 60-day lag between rainfall and transmission.
  • ▪A 22-year study of Bangladesh ending in 2022 found that temperature and rainfall in preceding months are closely linked to dengue transmission.

Subtopics

Vaccines and Immunization Policy18Vaccine development16Drug Approval and Clinical Trials12Drug Policy, Pricing & Approval12Clinical trials10Infectious Disease and Outbreaks8MRNA vaccine technology5Cancer immunotherapy4Pharma4Outbreak-Driven Vaccination3Clinical evaluation2Clinical Trial Design & Evaluation2Ebola outbreak2Infectious disease prevention2Personalized medicine2Pharmaceutical Industry2Public healthcare2Adolescent health1Antitrust & competition1Cancer & Oncology1Cancer treatment1Cancer treatment breakthroughs1COVID-19 vaccines1European Union1

Related timelines

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories

Strait of Hormuz blockage

148 stories